Floatz logo

Crisugabalin

Diabetic Peripheral Neuropathic Pain

Haisco Pharmaceutical Group Co., Ltd.Small moleculePhase 2/3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
81/ 100

Competitive context

27 Active assets in the Diabetic Peripheral Neuropathic Pain cohort.

Asset / SponsorPhaseRating
Duloxetine
Aga Khan University
Phase 4A
CYCLOHEXANEACETIC ACID, 1-(AMINOMETHYL)-
Aziende Chimiche Riunite Angelini Francesco S.p.A
Phase 4BBB
Duloxetine
Eli Lilly and Company
Phase 4BBB
ds-5565
Bangladesh Medical University
Phase 4BBB
Capsaicin
Corporacion Parc Tauli
Phase 4BBB

View all 50 →

Same molecule, other indications

Crisugabalin is also rated in:

postherpetic neuralgiaDormant
BB
Indicative ·
69 / 100
View asset →
Parkinson diseaseDormant
BB
Indicative ·
65 / 100
View asset →
peripheral neuropathyDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →